Sanofi Winthrop Industrie

Company snapshot

CE SANOFI WINTHROP is a pharma organization headquartered in ANTONY, FR. Primary therapeutic focus areas include Glycogen storage disease type II, Niemann-Pick disease. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1), phase 2 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sanofi Winthrop Industrie. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Sanofi Winthrop Industrie.

1. Jun 8, 2026 Clinical update

   PTA17333 — Approved

2. May 26, 2026 Clinical update

   Xenpozyme (olipudase alfa,GZ402665) — Phase 2

View all clinical trial activity →

• What is Sanofi Winthrop Industrie?

  CE SANOFI WINTHROP is a pharma organization headquartered in ANTONY, FR. Primary therapeutic focus areas include Glycogen storage disease type II, Niemann-Pick disease. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publi

• Is Sanofi Winthrop Industrie publicly traded?

  Sanofi Winthrop Industrie appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sanofi Winthrop Industrie develop or market?

  We link 6 drug profile(s) where Sanofi Winthrop Industrie is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sanofi-winthrop-industrie#company-drugs.

• What are the latest developments for Sanofi Winthrop Industrie?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sanofi Winthrop Industrie focus on?

  Sanofi Winthrop Industrie focuses on Glycogen storage disease type II, Niemann-Pick disease based on our analysis of their pipeline programs and drug development activities.